TACE联合射频消融治疗原发性肝癌患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.01.031

Abstract

Abstract: Objective The aim of this study was to investigate the efficacy of transcatheter hepatic chemoembolization (TACE) and radiofrequency ablation (RFA) in treatment of patients with primary liver cancer (PLC). Methods A total of 108 patients with PLC were recruited in our hospital between March 2016 and March 2018, and were randomly divided into two groups, with 54 in each, receiving TACE or TACE and RFA combination. All patients were followed-up for 12 months. Results After treatment, the effective rate and disease control rate in patients receiving TACE and RFA were 77.8% and 87.0%, significantly higher than 50.0% and 70.4%(P＜0.05) in TACE-treated group; one month after treatment, total serum bilirubin and alpha-fetoprotein levels in combination-treated group were (24.0±6.7)μmol/L and (135.7±15.6)μg/L, significantly lower than 【(28.3±8.2)μmol/L and (226.5±18.2)μg/L, respectively, P＜0.05) in TACE-treated group; during the treatment, the incidence in TACE- and RFA-treated patients was 48.2%, not significantly different compared to 51.9% in TACE-treated group (P＞0.05); the one-year survival rate in TACE- and RFA-treated patients was 75.0%(39/52), significantly higher than, 47.2%(25/53) in TACE-treated group (x²=8.542,P=0.003).Conclusion The application of TACE and RFA combination is safe and efficacious in the treatment of patients with PLC, which might prolong the survival of patients with PLC and warrants further investigation.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Radiofrequency ablation, Therapy

Qiao Min, Zhao Yijian,Z hang Jianqiao,et al. Efficacy of TACE and radiofrequency ablation combination in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2021, 24(1): 119-122.

References

[1] Facp MAC, Go TS, Kithier K, et al. Proceedings: primary liver cancer. areview of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases. Cancer, 1974, 33(2):574-582.
[2] Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology,2018, 67(2):600-611.
[3] Benzakoun J, Ronot M, Lagadec M, et al. Risks factors for severe pain after selective liver transarterial chemoembolization. Liver Int, 2017, 37(4):583-591.
[4] Kazutaka K, Naoki H, Akira Y, et al. Successful treatment of large-size advanced hepatocellular carcinoma by transarterial chemoembolization followed by the combination therapy of percutaneous ethanol-lipiodol injection and radiofrequency ablation. Oncol Rep, 2006, 16(5):1067-1070.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6):929-946.
[6] 閤谦, 吴骋, 童林军, 等. RECIST 1.1、PERCIST 1.0、WHO及EORTC用于评价结直肠癌肝脏转移化疗后疗效的比较. 中华核医学与分子影像杂志, 2017, 37(9):559-563.
[7] Shah B K, Kandel P, Khanal A. Second primary malignancies in hepatocellular cancer - a US population-based study. Anticancer Res, 2016, 36(7):3511-3514.
[8] Yamaguchi, Kuroda, Sugitani, et al. Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles. Int J Oncol, 2017, 50(5):1749-1759.
[9] Faigel DO, Lake DF, Landreth TL, et al. Eus-guided portal injection chemotherapy for treatment of hepatic metastases: feasibility in the acute porcine model. Gastrointest Endosc, 2016, 83(2):444-446.
[10] Lam C, Yuen W, Fan S. Hepatic cryosurgery for recurrent hepatocellular carcinoma after hepatectomy: a preliminary report. J Surg Oncol, 1998, 68(2):104-106.
[11] 赵金艳, 张一军, 刘学. 微波消融与射频消融对≤5cm单发小肝癌疗效的分析比较. 中华肿瘤防治杂志, 2018, 25(2):76-77.
[12] Aliberti C, Carandina R, Sarti D, et al. Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy. Anticancer Res, 2016, 36(7):3515-3521.
[13] Napoletano C, Taurino F, Biffoni M, et al. Rfa strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol, 2008, 32(2):481-490.
[14] 郭斌, 吴增城, 张宪光, 等. 肝动脉栓塞化疗治疗肝癌的应用进展. 中华肝胆外科杂志, 2016, 22(2):137-141.
[15] 王永华, 吴庭苗. 经导管肝动脉化疗栓塞术联合125I放射性粒子治疗肝癌的临床应用现状及进展. 中华核医学与分子影像杂志, 2019, 39(2):112-115.
[16] Zhang R, Tian X, Qin L, et al. Factors predictingabnormal liver function tests induced by graves’disease alone: a retrospective cohort study. Medicine (Baltimore), 2015, 94(19):e839.
[17] Hira K, Tariq RM, Sultana V, et al. Effect of seaweeds occurring at Karachi coast on mosquito larvae and liver function in rats. Pak J Pharm Sci, 2017, 30(2):387-391.
[18] Neel HB, Ritts RE. Transfer of tumor-specific immunity with syngeneic spleen cells and serum from mice that have large tumors and metastases. Cancer, 1977, 40(4):1643-1649.
[19] Hude I, Sasse S, Engert A, et al. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica, 2017, 102(1):30-42.
[20] Hofer U . Microbiome: the microbiota's cryptic message. Nat Rev Microbiol, 2017, 15(12):708-709.

Efficacy of TACE and radiofrequency ablation combination in the treatment of patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Xiaoyan, Hu Heping. Internal management of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 1-3.
[2]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[3]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[4]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[5]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[6]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[7]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[8]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[9]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[10]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[11]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[12]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[13]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[14]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[15]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.